Close Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

ShangPharma

Overview

Unlock datapoints

Portfolio analytics

Team

Investments

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.

Looking for a perfect list of funds?

Get recommendations from our smart algorithm

Get the list
Total investments 6
Average round size
info
The average size of a deal this fund participated in
$40M
Portfolio companies 4
Rounds per year 0.30
Lead investments 0
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.33
Exits 1
Key employees Soon

Areas of investment

  • Health Care
  • Biotechnology
  • Therapeutics
  • Medical
  • Clinical Trials
Summary

ShangPharma appeared to be the Corporate Investor, which was created in 2002. The company was established in Asia in China. The leading representative office of defined Corporate Investor is situated in the Shanghai.

The common things for fund are deals in the range of 10 - 50 millions dollars. The top activity for fund was in 2016. Opposing the other organizations, this ShangPharma works on 4 percentage points less the average amount of lead investments. The increased amount of exits for fund were in 2019. The fund is constantly included in less than 2 investment rounds annually.

The usual cause for the fund is to invest in rounds with 5-6 partakers. Despite the ShangPharma, startups are often financed by Timothy A. Springer, Schrodinger, Polaris Partners. The meaningful sponsors for the fund in investment in the same round are Vertex Ventures HC, Vertex Ventures, Timothy A. Springer. In the next rounds fund is usually obtained by Whitesun Healthcare Ventures, WI Harper Group, Timothy A. Springer.

Among the most popular portfolio startups of the fund, we may highlight Obsidian Therapeutics, Circle Pharma, Morphic Therapeutic. For fund there is no match between the country of its foundation and the country of its the most frequent investments - United States. Besides, a startup requires to be at the age of 2-3 years to receive the investment from the fund. The fund has no specific favorite in a number of founders of portfolio startups. If startup sums 4 or 5+ of the founder, the chance for it to be financed is low. We can highlight the next thriving fund investment areas, such as Pharmaceutical, Biotechnology.

Read more

Look at other 50 related and similar funds Collapse list
Fund NameLocation
Alpha Technologies Bellingham, United States, Washington
Apicap France, Ile-de-France, Paris
Asian Gateway Investments -
Blazar Ventures LLC Alexandria, United States, Virginia
Capital Medica Ventures Chiyoda, Japan
Fjord Ventures California, Laguna Hills, United States
Foundamental -
Galaxy Finance Holding Group -
InnovaFonds Corenc, France, Rhone-Alpes
Kun Lun Stone Capital China, Guangdong, Shenzhen
Lumar Ilford, Redbridge, United Kingdom
Maersk Line Copenhagen, Denmark, Hovedstaden
Majid Al Futtaim Holdings LLC. Dubai, United Arab Emirates
Riverhead Capital India, Maharashtra, Mumbai
Tenex Medical Investors Burlingame, California, United States
UNITED VENTURE CAPITAL Japan, Tokyo
University Hospital Ventures Cleveland, Ohio, United States
Zhongjinchuanhua (Ningbo) Industry Equity Investment Fund China, Ningbo, Zhejiang

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

Circle Pharma

Biotechnology
Clinical Trials
Health Care
Therapeutics
$45M17 Mar 2020 San Francisco, California, United States

Morphic Therapeutic

Biotechnology
Health Care
Medical
Therapeutics
$80M25 Sep 2018 Massachusetts, United States

APRINOIA Therapeutics

Biotechnology
Health Care
Health Diagnostics
Therapeutics
$11M16 Jan 2018 New Taipei

Obsidian Therapeutics

Biotechnology
Health Care
Pharmaceutical
$49M06 Dec 2017 Cambridge, Massachusetts, United States

Circle Pharma

Biotechnology
Clinical Trials
Health Care
Therapeutics
$4M21 Dec 2016 San Francisco, California, United States

Morphic Therapeutic

Biotechnology
Health Care
Medical
Therapeutics
$51M30 Jun 2016 Massachusetts, United States

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent ShangPharma?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

Wait!
You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: